Targeted imaging of myocardial damage

Nature Clinical Practice Cardiovascular Medicine

Volumn 5, Issue SUPPL. 2, 2008, Pages

  Sosnovik, David E ^a   Nahrendorf, Matthias ^a   Weissleder, Ralph ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN; CATHEPSIN B; CATHEPSIN K; CATHEPSIN S; CYSTEINE PROTEINASE; GADOLINIUM; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN F(AB) FRAGMENT; INDIUM 111; LIPOCORTIN 5; MATRIX METALLOPROTEINASE; MYELOPEROXIDASE; MYOSIN ANTIBODY; NANOPARTICLE; PLASMIN; SUPERPARAMAGNETIC IRON OXIDE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TECHNETIUM 99M; THROMBIN; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UROKINASE;

ARTICLE; CELL SURFACE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG TARGETING; ENZYME RELEASE; FLUORESCENCE MICROSCOPY; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HUMAN; INTRACARDIAC THROMBOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; SENSITIVITY ANALYSIS; SIGNAL PROCESSING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; CARDIOVASCULAR DISEASES; HEART; HUMANS; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 48349127474     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio1115     Document Type: Article

References (36)

1. Sosnovik DE et al. (2007) Molecular magnetic resonance imaging in cardiovascular medicine. Circulation 115: 2076-2086
2. Wu JC et al. (2007) Cardiovascular molecular imaging. Radiology 244: 337-355
3. Jaffer FA and Weissleder R (2005) Molecular imaging in the clinical arena. JAMA 293: 855-862
4. Wagner A et al. (2003) Contrast-enhanced MRI and routine single photon emission computed tomography (SPECT) perfusion imaging for detection of subendocardial myocardial infarcts: An imaging study. Lancet 361: 374-379
5. Meoli DF et al. (2004) Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest 113: 1684-1691
6. Su H et al. (2005) Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 112: 3157-3167
7. Khaw BA et al. (1980) Myocardial infarct imaging of antibodies to canine cardiac myosin with indium-111-diethylenetriamine pentaacetic acid. Science 209: 295-297
8. Khaw BA et al. (1986) Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. Circulation 74: 501-508
9. Hofstra L et al. (2000) Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 356: 209-212
10. Narula J et al. (2001) Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 7: 1347-1352
11. Nahrendorf M et al. (2006) Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 113: 1196-1202
12. Shah DJ et al. (2005) Technology insight: MRI of the myocardium. Nat Clin Pract Cardiovasc Med 2: 597-605
13. Einstein AJ et al. (2007) Estimating risk of cancer associated with radiation exposure from 64-slice computed tomography coronary angiography. JAMA 298: 317-323
14. Shen T et al. (1993) Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties. Magn Reson Med 29: 599-604
15. Wunderbaldinger P et al. (2002) Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug Chem 13: 264-268
16. Weissleder R et al. (1992) Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 182: 381-385
17. Schellenberger EA et al. (2004) Magneto/optical annexin V, a multimodal protein. Bioconjug Chem 15: 1062-1067
18. Sosnovik DE et al. (2005) Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magnetooptical nanoparticle. Magn Reson Med 54: 718-724
19. Hiller KH et al. (2006) Assessment of cardiovascular apoptosis in the isolated rat heart by magnetic resonance molecular imaging. Mol Imaging 5: 115-121
20. Nahrendorf M et al. (2007) Dual channel optical tomographic imaging of leukocyte recruitment and protease activity in the healing myocardial infarct. Circ Res 100: 1218-1225
21. Weissleder R et al. (2005) Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol 23: 1418-1423
22. Sosnovik DE et al. (2007) Fluorescence tomography and magnetic resonance imaging of myocardial macrophage infiltration in infarcted myocardium in vivo. Circulation 115: 1384-1391
23. Kanno S et al. (2001) Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation 104: 934-938
24. Chen JW et al. (2006) Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. Radiology 240: 473-481
25. Weissleder R and Ntziachristos V (2003) Shedding light onto live molecular targets. Nat Med 9: 123-128
26. Dumont EA et al. (2001) Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. Nat Med 7: 1352-1355
27. Ohnishi S et al. (2006) Intraoperative detection of cell injury and cell death with an 800 nm near-infrared fluorescent annexin V derivative. Am J Transplant 6: 2321-2331
28. Chen J et al. (2005) Near-infrared fluorescent imaging of matrix metalloproteinase activity after myocardial infarction. Circulation 111: 1800-1805
29. Harisinghani MG et al. (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348: 2491-2499
30. Kooi ME et al. (2003) Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107: 2453-2458
31. Trivedi RA et al. (2004) In vivo detection of macrophages in human carotid atheroma: Temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke 35: 1631-1635
32. Shamsi K et al. (2006) A summary of safety of gadofosveset (MS-325) at 0.03 mmol/kg body weight dose: Phase II and phase III clinical trials data. Invest Radiol 41: 822-830
33. Botnar RM et al. (2004) In vivo molecular imaging of acute and subacute thrombosis using a fibrinbinding magnetic resonance imaging contrast agent. Circulation 109: 2023-2029
34. Katoh M et al. (2007) Molecular MRI of thrombosis using novel fibrin-specific contrast agent: Initial results in humans at 3.0 T. Proc Int Soc Magn Reson 9: 100
35. Pichler BJ et al. (2006) Performance test of an LSOAPD detector in a 7-T MRI scanner for simultaneous PET/MRI. J Nucl Med 47: 639-647
36. Kircher MF et al. (2003) A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 63: 8122-8125